Corium, Lotus Pharmaceutical seal deal for Alzheimer’s drug ADLARITY in Asia
Corium, a biopharmaceutical frontrunner in the neuroscience arena, and Lotus Pharmaceutical, a global pharmaceutical powerhouse, have declared a collaboration and license agreement. This pact centers ... Read More
Suven Life Sciences begins Masupirdine phase 3 clinical trial in dementia patients
Suven Life Sciences has started a global phase 3 clinical trial of Masupirdine in dementia of the Alzheimer's type by randomizing the first patient. According ... Read More
MGC Pharmaceuticals signs supply deal with AMC for phytomedicine products
MGC Pharmaceuticals, a developer of phytocannabinoid-derived medicines, has signed a $24 million supply and distribution deal with US-based AMC Holdings. The deal is for the ... Read More
Suven Life Sciences to launch phase 3 clinical trial for Masupirdine
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression ... Read More
Eli Lilly completes $1.04bn acquisition of Prevail Therapeutics to expand gene therapy program
Eli Lilly and Company has officially finalized its acquisition of Prevail Therapeutics in a deal valued at up to $1.04 billion. This acquisition represents a ... Read More
PostEra, NeuroLucent to partner on identifying small-molecule therapeutics for Alzheimer’s
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer's disease ... Read More
PostEra, NeuroLucent to partner on identifying small-molecule therapeutics for Alzheimer’s
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer’s disease ... Read More
Daily intake of citrus fruits like orange and grapes cut risk of dementia
As per the recent study published in journal of Nutrition, daily intake of fruits like orange and grapes by the adults can cut the risk ... Read More